Hematology · Cold Agglutinin Disease

Primary CAD vs. Secondary CAS: Finding the Root Cause

At a Glance

Primary Cold Agglutinin Disease (CAD) is a chronic bone marrow disorder, while Secondary Syndrome (CAS) is a reaction to an infection or cancer. A bone marrow biopsy is required to differentiate the two, ensuring you receive the correct targeted treatment or care for the underlying trigger.

When you are first diagnosed with cold agglutinins, one of the most important tasks for your medical team is to determine if you have Primary Cold Agglutinin Disease (CAD) or Secondary Cold Agglutinin Syndrome (CAS) ^[1]^[2]. While they share a similar name and symptoms, they are fundamentally different conditions with very different treatment paths.

Primary CAD: A Root in the Bone Marrow

Primary CAD is considered a “clonal B-cell lymphoproliferative disorder” ^[1]^[3].

The Cause: It is not caused by an outside infection. Instead, it starts in your bone marrow, where a small group (or “clone”) of B-cells begins producing the monoclonal IgM antibodies that attack your red blood cells ^[2]^[4].
The Nature: While it is a disorder of the bone marrow, it is typically slow-growing and lacks the aggressive features of an overt malignancy or cancer ^[2].
The Course: It is a chronic, long-term condition ^[5].

Secondary CAS: A Reaction to a Trigger

Secondary CAS is a “reactionary” condition. It happens because your immune system is responding to an external “invader” or another medical issue ^[1].

Infection Triggers: It often appears suddenly after an infection, such as Mycoplasma pneumoniae (walking pneumonia), Epstein-Barr virus (mononucleosis), or COVID-19 ^[6]^[7]^[8].
Malignancy Triggers: It can also be caused by underlying cancers, such as chronic lymphocytic leukemia (CLL) or certain types of lymphoma ^[6]^[9].
The Course: If the trigger is an infection, the syndrome is often temporary and may resolve on its own once the infection is gone ^[10].

Why the Distinction Matters for Treatment

The treatment strategy for these two conditions is completely different. If you have Secondary CAS, doctors will focus almost entirely on treating the underlying cause (like curing the pneumonia or managing the lymphoma) ^[8]^[11].

If you have Primary CAD, the treatment must address the disease itself:

Targeting the B-cells: Using therapies like rituximab to clear out the specific B-cells in the bone marrow that are producing the antibodies ^[12]^[13].
Targeting the Complement System: Using newer drugs like sutimlimab to block the “classical complement pathway” in the blood, stopping the destruction of red blood cells quickly ^[14]^[15].

The Diagnostic “Gold Standard”: Bone Marrow Biopsy

To tell these two apart, a bone marrow biopsy is often necessary ^[16]. This procedure allows your doctor to look directly at the factory where your blood is made.

Identifying the Clone: Pathologists use a technique called flow cytometry to see if there is a specific “clone” of B-cells, which confirms primary CAD ^[1]^[2].
Rule Out Other Conditions: The biopsy helps rule out other serious bone marrow issues or cancers that could be causing secondary CAS ^[17]^[18].
Genetic Markers: Doctors may also look for specific genetic mutations, such as the MYD88 mutation. They test for this primarily to rule out other cancers like Waldenström’s Macroglobulinemia, as primary CAD is typically MYD88-negative ^[19]^[20].

Feature	Primary CAD	Secondary CAS
Origin	Bone marrow (clonal B-cells)	Outside trigger (infection/cancer)
Duration	Chronic (long-term)	Often temporary (if infectious)
Primary Treatment	B-cell or complement therapy	Treating the underlying cause
Biopsy Result	Specific clonal B-cell population	No specific CAD clone (or shows other cancer)

By confirming which version you have, your care team can ensure you aren’t undergoing unnecessary treatments for a temporary infection, or conversely, that your chronic condition is being managed with the most effective modern therapies.

Common questions in this guide

What is the difference between primary CAD and secondary CAS?

Primary CAD is a chronic disorder that starts in the bone marrow, where abnormal B-cells produce antibodies that attack red blood cells. Secondary CAS is a temporary reaction to an external trigger, such as an infection or another underlying cancer.

How do doctors diagnose primary Cold Agglutinin Disease?

Doctors typically use a bone marrow biopsy to diagnose primary CAD. Pathologists examine the sample using flow cytometry to look for a specific clone of B-cells, which confirms the primary disease and rules out other conditions.

How are the treatments for primary CAD and secondary CAS different?

Secondary CAS is treated by addressing its underlying trigger, like curing an infection or managing a separate cancer. Primary CAD requires therapies that target the disease itself, using medications that clear out specific B-cells in the bone marrow or block the complement system in the blood.

Will my secondary cold agglutinin syndrome go away on its own?

If your secondary CAS was triggered by a viral or bacterial infection, it is often temporary. Once the underlying infection is successfully treated or resolves, the cold agglutinins usually disappear on their own.

Why is a MYD88 mutation test performed for cold agglutinins?

Doctors test for the MYD88 genetic mutation mainly to rule out other blood cancers like Waldenström's Macroglobulinemia. Primary CAD is typically negative for the MYD88 mutation, which helps your care team confirm the correct diagnosis.

Curated prompts to bring to your next appointment.

1.Do my test results point toward primary Cold Agglutinin Disease or secondary Cold Agglutinin Syndrome?
2.If this is secondary CAS, what is the underlying trigger (infection, autoimmune issue, or another condition) we need to treat?
3.Was my bone marrow biopsy evaluated with flow cytometry and immunohistochemistry to look for a 'clonal B-cell population'?
4.Was a MYD88 mutation test performed on my bone marrow sample, and what did it show?
5.If this is primary CAD, are we targeting the B-cells in my bone marrow (like rituximab) or the complement system in my blood (like sutimlimab)?
6.If this is secondary to an infection, how long should we wait for the cold agglutinins to disappear on their own?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (20)

1
Diagnosis and management of cold agglutinin disease.
Berentsen S
Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.
PMID: 41348049
2
Cold agglutinin syndrome secondary to splenic marginal zone lymphoma: a case report.
Portich JP, Blos B, Sekine L, Franz JPM
Hematology, transfusion and cell therapy 2023; (45(3)):403-405 doi:10.1016/j.htct.2021.07.009.
PMID: 34836848
3
The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms.
Berentsen S, Vos JMI, Malecka A, et al.
Expert review of hematology 2024; (17(8)):479-492 doi:10.1080/17474086.2024.2372333.
PMID: 38938203
4
Cold agglutinin disease: where do we stand, and where are we going?
Berentsen S, Malecka A, Randen U, Tjønnfjord GE
Clinical advances in hematology & oncology : H&O 2020; (18(1)):35-44.
PMID: 32511221
5
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.
Bylsma LC, Gulbech Ording A, Rosenthal A, et al.
Blood advances 2019; (3(20)):2980-2985 doi:10.1182/bloodadvances.2019000476.
PMID: 31648316
6
Cold Agglutinin Syndrome as the Initial Presentation of Acute Myeloid Leukemia: A Case Report.
Sadeghi MV, Vosough Z, Jahansouz D
Clinical case reports 2025; (13(10)):e71061 doi:10.1002/ccr3.71061.
PMID: 41036160
7
[Cold agglutinin syndrome associated with infectious mononucleosis: A case report].
Garzón-Recalde DA, Rentería-Castillo E, Anda-Garay JC
Revista medica del Instituto Mexicano del Seguro Social 2024; (62(1)):1-7.
PMID: 39116196
8
Autoimmune hemolytic anemia associated with herpes zoster.
Baba Y, Kamata A, Kouno M, Takahashi S
The Journal of dermatology 2023; (50(3)):e94-e95 doi:10.1111/1346-8138.16594.
PMID: 36152300
9
Intervascular Large B-cell Lymphoma with Severe Anemia and a High-titer of Cold Agglutinin.
Oka T, Tsuji Y, Sakai T, et al.
Internal medicine (Tokyo, Japan) 2025; (64(22)):3279-3283 doi:10.2169/internalmedicine.5340-25.
PMID: 40368791
10
Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study (MyCOLD Study).
Chevalier K, Holub M, Palich R, et al.
American journal of hematology 2025; (100(9)):1557-1565 doi:10.1002/ajh.70010.
PMID: 40682504
11
Role of Complement in Autoimmune Hemolytic Anemia.
Berentsen S
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2015; (42(5)):303-10 doi:10.1159/000438964.
PMID: 26696798
12
Autoimmune hemolytic anemia.
Hill A, Hill QA
Hematology. American Society of Hematology. Education Program 2018; (2018(1)):382-389 doi:10.1182/asheducation-2018.1.382.
PMID: 30504336
13
Hot therapy for cold agglutinin disease.
Jaeger U
Blood 2017; (130(4)):392-393 doi:10.1182/blood-2017-06-788463.
PMID: 28751358
14
Sutimlimab in Cold Agglutinin Disease.
Röth A, Barcellini W, D'Sa S, et al.
The New England journal of medicine 2021; (384(14)):1323-1334 doi:10.1056/NEJMoa2027760.
PMID: 33826820
15
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
Berentsen S, Barcellini W, D'Sa S, Jilma B
Immunotherapy 2022; (14(15)):1191-1204 doi:10.2217/imt-2022-0085.
PMID: 35946351
16
An Extensive Analysis and Comparison of Bone Marrow Aspiration and Bone Marrow Trephine Biopsy at a Tertiary Care Hospital in Jharkhand for Various Hematological and Non-hematological Illnesses.
Jawed MA, Paswan MK, Mahto SK, et al.
Cureus 2024; (16(6)):e62661 doi:10.7759/cureus.62661.
PMID: 39036242
17
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Elba S, Castellino A, Soriasio R, et al.
Journal of medical case reports 2020; (14(1)):75 doi:10.1186/s13256-020-02380-2.
PMID: 32564775
18
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al.
Journal of clinical pathology 2020; (73(9)):571-577 doi:10.1136/jclinpath-2019-206282.
PMID: 31980558
19
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.
Garcia-Sanz R, Varettoni M, Jiménez C, et al.
Seminars in hematology 2023; (60(2)):90-96 doi:10.1053/j.seminhematol.2023.03.007.
PMID: 37099028
20
Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis.
García-Abellás P, Ferrer Gómez A, Bueno Sacristán D, et al.
EJHaem 2022; (3(4)):1181-1187 doi:10.1002/jha2.573.
PMID: 36467836

This page explains the differences between primary CAD and secondary CAS for educational purposes. Always consult your hematologist or oncologist for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Autoimmune hemolytic anemia, cold type.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents